How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/treatment-of-gastroesophageal-reflux-disease-gerd-in-patients-who-have-not-responded-adequately-to-proton-pump-inhibitor-ppi-therapy.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatm

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Palazestrant	palazestrant	Pfizer Inc.	estrogen receptor antagonist and degrader	estrogen receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer Inc. · 1 drug in Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy:

Cite this brief

Drug Landscape (2026). Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-gastroesophageal-reflux-disease-gerd-in-patients-who-have-not-responded-adequately-to-proton-pump-inhibitor-ppi-therapy. Accessed 2026-06-10.

Treatment of gastroesophageal reflux disease (GERD) in patients who have not responded adequately to proton pump inhibitor (PPI) therapy full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing